We have now completed two engaging days at the World Evidence, Pricing and Access Congress
The conversations have been thoughtful, forward-looking, and grounded in the realities of access across Europe.
AI in evidence generation, implementation of Joint Clinical Assessment JCA, and ongoing discussions around MFN continue to shape the agenda.
A sincere thank you to our colleagues from IGES Pharma. Working side by side as part of the athagoras Group reflects the strength of our combined expertise and shared commitment to rigorous, decision-ready evidence.
Collaboration across markets and disciplines is increasingly essential in today’s access landscape.
Thank you to everyone who took the time to connect with us in Amsterdam.
What developments do you believe will most influence pricing and access strategy in the coming year?
